Download PDF

1. Company Snapshot

1.a. Company Description

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis.It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.The company was formerly known as Home Dialysis Plus, Ltd.


and changed its name to Outset Medical, Inc.in January 2015.Outset Medical, Inc.


was incorporated in 2003 and is headquartered in San Jose, California.

Show Full description

1.b. Last Insights on OM

The recent 3 months performance of Outset Medical, Inc. was negatively impacted by a Warning Letter from the FDA in July 2023, which was only recently resolved on February 13, 2025. This regulatory issue likely weighed on investor sentiment and may have contributed to the company's Q4 loss. Additionally, the company's decision to announce a one-for-fifteen reverse stock split on March 18, 2025, may have been perceived as a negative development by some investors.

1.c. Company Highlights

2. Outset Medical's Q4 2025 Earnings: A Closer Look at the Numbers

Outset Medical reported revenue of $119.5 million for 2025, representing a 5% growth, with non-GAAP gross margin expanding to 39.6%. The company's fourth-quarter revenue was $28.9 million, with product revenue growing 11% to $6.4 million and consumable sales rebounding sequentially. Non-GAAP gross margin expanded by 500 basis points to 42.9%, and non-GAAP operating expenses declined by 4% to $25.7 million. The company's EPS came out at -$1.09396, missing estimates of -$0.45.

Publication Date: Mar -05

📋 Highlights
  • 2025 Revenue Growth: Revenue increased 5% to $119.5 million, with Q4 revenue at $28.9 million.
  • Product Revenue Expansion: Product revenue rose 11% to $6.4 million in Q4, driven by in-sourcing dialysis agreements.
  • Gross Margin Improvement: Non-GAAP gross margin expanded 500 basis points to 42.9% in Q4, with 2026 guidance targeting low to mid-40%.
  • 2026 Revenue Guidance: Anticipated revenue range of $125–130 million, reflecting 5–9% growth across all revenue components.
  • Tablo Platform Impact: Next-gen Tablo system expected to enhance cybersecurity and drive margin gains post-launch in Q2 2026.

Financial Performance Highlights

The company's financial results demonstrate a mixed bag, with revenue growth and margin expansion being notable positives. However, the EPS miss is a concern. As Leslie Trigg mentioned, "We've seen a significant impact on critical access hospitals, which are increasingly looking to establish new dialysis service lines due to the closure of local clinics." This trend is expected to drive growth in the coming quarters.

Valuation Metrics

Outset Medical's valuation metrics are worth examining. The stock trades at a P/S Ratio of 0.54, EV/EBITDA of -2.2, and P/E Ratio of -0.77. These metrics suggest that the market is pricing in significant growth expectations, but the negative earnings and cash flow metrics are a concern. The company's ROE and ROIC are also negative, at -54.99% and -29.05%, respectively.

Growth Prospects

The company expects revenue to be in the range of $125 million to $130 million for 2026, representing a growth rate of 5-9%. Analysts estimate revenue growth of 11.2% for the next year. The company's pipeline shows good diversification between large brand-name health systems and medium-sized and small hospitals. The emerging clinical value proposition is expected to drive growth, with published evidence showing a reduction in length of stay, CLABSI rates, and code blues during dialysis treatment.

Next-Generation Tablo Platform

The company's next-generation Tablo platform is expected to be a tailwind, particularly in terms of cybersecurity. The new system includes physical network cloud connections, new security controls, and round-the-clock cyber monitoring. The device performance and reliability improvements will improve uptime, which in turn will improve the user experience and patient care. The new Tablo is expected to be margin-accretive once fully launched.

3. NewsRoom

Card image cap

NOTICE TO THE HOLDERS of CH1108679908, Series 6800, Open ended Valour Mantra (OM) SEK (the “Certificates”) issued by Valour Inc., LEI: 984500RAH11EE88V4014 (the “Issuer”)

Feb -24

Source: globenewswire.com

Card image cap

Outset Medical, Inc. (NASDAQ:OM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Feb -19

Source: defenseworld.net

Card image cap

Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript

Feb -12

Source: seekingalpha.com

Card image cap

Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results

Feb -11

Source: globenewswire.com

Card image cap

Analyzing KORU Medical Systems (NASDAQ:KRMD) and Outset Medical (NASDAQ:OM)

Feb -08

Source: defenseworld.net

Card image cap

OM Stock Gains on FDA Clearance for Next-Gen Tablo Dialysis System

Jan -28

Source: zacks.com

Card image cap

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned

Jan -27

Source: globenewswire.com

Card image cap

Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

Jan -26

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.28%)

6. Segments

Consoles

Expected Growth: 9.27%

Outset Medical's Consoles growth is driven by increasing adoption in dialysis clinics, expanding product portfolio, and strategic partnerships. The rising demand for home dialysis and growing need for cost-effective solutions also contribute to the growth. Additionally, the company's focus on innovation and customer-centric approach have led to increased market share and revenue growth.

Consumables

Expected Growth: 8.9%

Outset Medical's Consumables segment growth of 8.9% is driven by increasing adoption of its Tablo Hemodialysis System, expansion into new dialysis clinics, and growing demand for home dialysis treatment. Additionally, the company's strategic partnerships and investments in product development have enhanced its offerings, contributing to the segment's growth.

Service and Other

Expected Growth: 9.9%

Outset Medical's 9.9% growth in Service and Other is driven by increasing adoption of its Tablo Hemodialysis System, expansion into new dialysis clinics, and growing demand for home dialysis services. Additionally, the company's focus on providing comprehensive service and maintenance support to its customers has led to increased revenue from service contracts and consumables sales.

7. Detailed Products

Tablo Hemodialysis System

A novel, all-in-one hemodialysis system designed for use in acute and chronic care settings, offering a more efficient and flexible treatment option for patients and healthcare providers.

Tablo Cartridge

A single-use, disposable cartridge that contains the dialysate and other necessary components for a single hemodialysis treatment, designed for use with the Tablo Hemodialysis System.

8. Outset Medical, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Outset Medical, Inc. faces moderate threat from substitutes, as patients may opt for alternative dialysis methods or delay treatment. However, the company's innovative technology and focus on home dialysis may mitigate this threat.

Bargaining Power Of Customers

Outset Medical, Inc.'s customers, primarily healthcare providers and patients, have limited bargaining power due to the company's unique technology and limited competition in the home dialysis market.

Bargaining Power Of Suppliers

Outset Medical, Inc. has a diversified supplier base, reducing dependence on individual suppliers and minimizing their bargaining power.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the medical device industry, including regulatory hurdles and significant R&D investments required to develop innovative technology.

Intensity Of Rivalry

The intensity of rivalry in the dialysis market is moderate, with a few established players competing for market share. However, Outset Medical, Inc.'s innovative technology and focus on home dialysis may help the company differentiate itself and gain a competitive advantage.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 52.57%
Debt Cost 9.28%
Equity Weight 47.43%
Equity Cost 13.12%
WACC 11.10%
Leverage 110.82%

11. Quality Control: Outset Medical, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
AdaptHealth

A-Score: 4.7/10

Value: 8.4

Growth: 6.4

Quality: 5.2

Yield: 0.0

Momentum: 5.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
PAVmed

A-Score: 3.6/10

Value: 9.8

Growth: 7.7

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Outset Medical

A-Score: 3.5/10

Value: 9.8

Growth: 5.0

Quality: 4.5

Yield: 0.0

Momentum: 1.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Cytosorbents

A-Score: 3.3/10

Value: 7.8

Growth: 4.7

Quality: 3.9

Yield: 0.0

Momentum: 2.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
CVRx

A-Score: 3.1/10

Value: 7.0

Growth: 4.7

Quality: 3.9

Yield: 0.0

Momentum: 1.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Pacific Biosciences

A-Score: 2.9/10

Value: 6.6

Growth: 2.2

Quality: 2.4

Yield: 0.0

Momentum: 5.5

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.16$

Current Price

3.16$

Potential

-0.00%

Expected Cash-Flows